Published in Br J Pharmacol on May 01, 1976
The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol (1978) 1.48
5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol (1993) 1.11
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol (1977) 1.10
A behavioural and biochemical study in rats of 5-hydroxytryptamine receptor agonists and antagonists, with observations on structure-activity requirements for the agonists. Br J Pharmacol (1981) 0.95
Pharmacological models of ADHD. J Neural Transm (Vienna) (2007) 0.82
Human behavioural arousal induced by dopamine. Br J Clin Pharmacol (1978) 0.75
Repeated exposure of rats to the convulsant agent flurothyl enhances 5-hydroxytryptamine- and dopamine-mediated behavioural responses. Br J Pharmacol (1978) 0.75
Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol (1970) 4.48
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res (1975) 2.89
Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand Suppl (1971) 2.79
A SENSITIVE METHOD FOR SPECTROPHOTOFLUOROMETRIC ASSAY OF CATECHOLAMINES. Int J Neuropharmacol (1964) 2.64
Stereotyped and circling behaviour induced by dopaminergic agonists after lesions of the midbrain raphe nuclei. Eur J Pharmacol (1974) 1.36
Microanalytical procedures for fluorometric assay of brain DOPA-5HTP decarboxylase, norepinephrine and serotonin, and a detailed mapping of decarboxylase activity in brain. J Neurochem (1961) 1.35
Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone. Science (1972) 1.31
Evidence for the functional interaction of two central neurotransmitters. Psychopharmacologia (1974) 1.29
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF). Life Sci I (1971) 1.23
The relative importance of dopaminergic and noradrenergic neuronal systems for the stimulation of locomotor activity induced by amphetamine and other drugs. Neuropharmacology (1973) 1.09
DL-5-hydroxytryptophan-induced changes in central monoamine neurons after peripheral decarboxylase inhibition. J Pharm Pharmacol (1971) 1.06
The effect of p-chloroamphetamine on motility in rats after inhibition of monoamine synthesis, storage, uptake and receptor interaction. Psychopharmacologia (1974) 1.00
TRH potentiates behavioural changes following increased brain 5-hydroxytryptamine accumulation in rats. Nature (1974) 0.99
Structural specificity for inhibition of [14C]-5-hydroxytryptamine uptake by cerebral slices. J Pharm Pharmacol (1970) 0.95
The effect of para-chlorophenylalanine on spontaneous locomotor activity in the rat. Neuropharmacology (1971) 0.94
Central and peripheral effects of 5-hydroxytryptophan on motor activity in mice. Psychopharmacologia (1972) 0.92
Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine. Br J Pharmacol (1974) 0.92
Tryptophan transport across the synaptosomal membrane. J Neurochem (1970) 0.91
On the mechanism of brain 5-hydroxytryptamine depletion by p-chloroamphetamine and related drugs and the specificity of their action. Adv Biochem Psychopharmacol (1974) 0.88
Kinetics of serotonin accumulation into synaptosomes of rat brain--effects of amphetamine and chloroamphetamines. Biochem Pharmacol (1973) 0.88
Different central mediation of the stimulant effects of amphetamine and its p-chloro analogue. Biochem Pharmacol (1968) 0.87
DL-[2-14C]p-chlorophenylalanine as an inhibitor of tryptophan 5-hydroxylase. J Neurochem (1970) 0.85
Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice. Pharmacol Biochem Behav (1974) 0.85
Behavioral, biochemical, and histochemical analyses of the central effects of monoamine precursors after peripheral decarboxylase inhibition. Brain Res (1972) 0.84
The role of monoamines in rotation induced or potentiated by amphetamine after nigral, raphe and mesencephalic reticular lesions in the rat brain. Neuropharmacology (1973) 0.83
Central decarboxylation and uptake of L-DOPA. Naunyn Schmiedebergs Arch Pharmacol (1972) 0.82
Recent studies with 4-chloramphetamine and some analogues. Adv Biochem Psychopharmacol (1974) 0.82
Apomorphine: modification of its hyperthermic effect in rabbits by p-chlorophenylalanine. Science (1974) 0.81
Thyrotropin releasing hormone: enhancement of DOPA activity in thyroidectomized rats. Life Sci (1974) 0.81
Unilateral 6-hydroxydopamine lesions of nigrostriatal or mesolimbic dopamine-containing terminals and the drug-induced rotation of rats. Brain Res (1975) 0.81
Effect of phenmetrazine, aminorex and ( ) p-chloramphetamine on the motor activity and turnover rate of brain catecholamines. Br J Pharmacol (1971) 0.80
p-Chloroamphetamine. Temporal relationship between psychomotor stimulation and metabolism of brain norepinephrine. Biochem Pharmacol (1970) 0.80
Is there a catecholamine-serotonin interaction in the control of locomotor activity? Neuropharmacology (1975) 0.79
Inhibition by p-chloroamphetamine of the conversion of 5-hydroxytryptamine to 5-hydroxyindoleacetic acid in rat brain. J Pharm Pharmacol (1970) 0.78
Comparative effects of P-chloroamphetamine and amphetamine on metabolism and in vivo release of 3 H-norepinephrine in the hypothalamus. Eur J Pharmacol (1971) 0.77
Proceedings: Biochemical evidence for the involvement of noradrenaline in motor activity produced by L-DOPA in rodents. Br J Pharmacol (1975) 0.77
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Cross-cultural primary care: a patient-based approach. Ann Intern Med (1999) 5.06
Importance of AMPA receptors for hippocampal synaptic plasticity but not for spatial learning. Science (1999) 4.56
Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol (1970) 4.48
Analysis of vertebrate SCL loci identifies conserved enhancers. Nat Biotechnol (2000) 4.01
A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene (2006) 3.21
Ecstasy and neurodegeneration. BMJ (1996) 2.93
Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res (1975) 2.89
Total synthesis of a human leukocyte interferon gene. Nature (1981) 2.76
How to improve plastic surgery knowledge, skills and career interest in undergraduates in one day. J Plast Reconstr Aesthet Surg (2009) 2.54
Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA(B(1)). Neuron (2001) 2.51
The SCL gene specifies haemangioblast development from early mesoderm. EMBO J (1998) 2.47
Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat (2012) 2.05
The mechanism of adenosine diphosphate induced platelet aggregation: binding to platelet receptors and inhibition of binding and aggregation by prostaglandin E 1 . J Physiol (1972) 2.05
Long-range comparison of human and mouse SCL loci: localized regions of sensitivity to restriction endonucleases correspond precisely with peaks of conserved noncoding sequences. Genome Res (2001) 2.04
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol (2006) 1.97
Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol (2005) 1.96
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat (2011) 1.74
Analysis of pineal and brain indole alkylamines by gas chromatography-mass spectrometry. Adv Biochem Psychopharmacol (1973) 1.71
Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature (1968) 1.69
An SCL 3' enhancer targets developing endothelium together with embryonic and adult haematopoietic progenitors. Development (1999) 1.67
The SCL gene: from case report to critical hematopoietic regulator. Blood (1999) 1.65
Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol (2009) 1.60
Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood (2000) 1.58
Selective 6OHDA-induced destruction of mesolimbic dopamine neurons: abolition of psychostimulant-induced locomotor activity in rats. Eur J Pharmacol (1976) 1.57
Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology (2007) 1.57
Cephalosporin-induced immune neutropenia. Br J Haematol (1985) 1.56
Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype. Br J Cancer (2008) 1.55
Short-term primary culture of epithelial cells derived from human breast tumours. Br J Cancer (1998) 1.51
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol (1978) 1.48
Environmental impacts and sustainability of egg production systems. Poult Sci (2011) 1.46
A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol (1985) 1.43
Tumour-infiltrating macrophages and clinical outcome in breast cancer. J Clin Pathol (2011) 1.41
The effect of tryptophan metabolites on brain 5-hydroxytryptamine metabolism. Biochem Pharmacol (1970) 1.41
Distinct 5' SCL enhancers direct transcription to developing brain, spinal cord, and endothelium: neural expression is mediated by GATA factor binding sites. Dev Biol (1999) 1.41
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol (1975) 1.38
Selective rescue of early haematopoietic progenitors in Scl(-/-) mice by expressing Scl under the control of a stem cell enhancer. Development (2001) 1.37
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol (1995) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke. Int J Stroke (2009) 1.32
Molecular cloning and chromosomal localization of the murine homolog of the human helix-loop-helix gene SCL. Proc Natl Acad Sci U S A (1991) 1.32
The pharmacology of the hypothermic response in mice to 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). A model of presynaptic 5-HT1 function. Neuropharmacology (1985) 1.30
The Ets1 transcription factor is widely expressed during murine embryo development and is associated with mesodermal cells involved in morphogenetic processes such as organ formation. Proc Natl Acad Sci U S A (1993) 1.28
Hypertension in multicultural and minority populations: linking communication to compliance. Curr Hypertens Rep (1999) 1.28
Letter: Factors influencing effect of hydrocortisone on rat brain tryptophan metabolism. Nature (1975) 1.27
Epidemiology of burns in childhood. Burns Incl Therm Inj (1984) 1.27
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature (1976) 1.26
Lineage-restricted regulation of the murine SCL/TAL-1 promoter. Blood (1995) 1.25
mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Mol Psychiatry (2007) 1.24
3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose. Psychopharmacology (Berl) (2001) 1.22
Molecular characterization of NSCL, a gene encoding a helix-loop-helix protein expressed in the developing nervous system. Proc Natl Acad Sci U S A (1992) 1.21
Regulation of the stem cell leukemia (SCL) gene: a tale of two fishes. Proc Natl Acad Sci U S A (2001) 1.20
Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. Br J Haematol (1997) 1.17
Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study. Breast Cancer Res Treat (2011) 1.17
Transcriptional regulation of the SCL locus: identification of an enhancer that targets the primitive erythroid lineage in vivo. Mol Cell Biol (2005) 1.16
In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine. Br J Pharmacol (1997) 1.14
The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur J Pharmacol (1995) 1.13
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer (2012) 1.13
The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol (1974) 1.13
The SCL +40 enhancer targets the midbrain together with primitive and definitive hematopoiesis and is regulated by SCL and GATA proteins. Mol Cell Biol (2007) 1.13
Attenuation by chlormethiazole administration of the rise in extracellular amino acids following focal ischaemia in the cerebral cortex of the rat. Br J Pharmacol (1994) 1.13
Distinct mechanisms direct SCL/tal-1 expression in erythroid cells and CD34 positive primitive myeloid cells. J Biol Chem (1997) 1.13
The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology (1975) 1.13
Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12
The relative attenuation of self-stimulation, eating and drinking produced by dopamine-receptor blockade. Psychopharmacologia (1974) 1.12
5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br J Pharmacol (1993) 1.11
Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol (1980) 1.11
Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharmacology (Berl) (1979) 1.11
Alterations in GABA metabolism and Met-enkephalin content in rat brain following repeated electroconvulsive shocks. J Neurochem (1978) 1.10
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br J Pharmacol (1977) 1.10
Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood (1994) 1.10
The pharmacokinetic profile of lithium in rat and mouse; an important factor in psychopharmacological investigation of the drug. Neuropharmacology (1986) 1.09
The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology (1998) 1.09
MicroRNA involvement in the pathogenesis and management of breast cancer. J Clin Pathol (2009) 1.08
NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke (2001) 1.08
Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology. J Pharmacol Exp Ther (2009) 1.08
Mesolimbic dopaminergic neurones in the rotational model of nigrostriatal function. Nature (1976) 1.08
Effects of intracranial dopamine perfusion: behavioural arousal and reversal of cerebral arterial spasm following surgery for clipping of ruptured cerebral aneurysms. Proc R Soc Med (1977) 1.08
Regional rat brain benzodiazepine receptor number and gamma-aminobutyric acid concentration following a convulsion. Br J Pharmacol (1982) 1.07
Transcriptional regulation of the stem cell leukemia gene by PU.1 and Elf-1. J Biol Chem (1998) 1.06
Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol (2002) 1.06
Neuroprotective activity of chlormethiazole following transient forebrain ischaemia in the gerbil. Br J Pharmacol (1991) 1.06
The contrasting actions of TRH and cycloheximide in altering the effects of centrally acting drugs: evidence for the non-involvement of dopamine sensitive adenylate cyclase. Neuropharmacology (1976) 1.05
Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol (1998) 1.05
Studies on the post-ictal rise in seizure threshold. Eur J Pharmacol (1981) 1.05
Philadelphia-negative chronic myeloid leukaemia: detection by FISH of BCR-ABL fusion gene localized either to chromosome 9 or chromosome 22. Br J Haematol (1994) 1.04
The effects of chlormethiazole and nimodipine on cortical infarct area after focal cerebral ischaemia in the rat. Neuroscience (1993) 1.04
A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res Treat (2009) 1.03
Efficacy of disodium 4-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology (2001) 1.03